Company intelligence / Profile preview
Cambium Oncology
Atlanta, Georgia, United Statescambiumoncology.com ↗
- Ownership
- Private
- Employees
- ~42
- Development stage
- Other
01
Overview
Cambium Oncology’s lead program, ANT308, has shown strong single-agent anti-leukemia activity in mouse models and synergistic effects with anti-PD‑1 checkpoint inhibitors in pancreatic cancer models. The company reports no toxicity-limiting dosages observed preclinically. Their approach includes biomarker-driven patient selection and combination strategies to overcome tumor resistance mechanisms
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeImmunotherapyCheckpoint inhibitorImmune-modulating agent
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →03
Partnerships
Winship Cancer Center at Emory University
Beyond the preview
Go deeper on Cambium Oncology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cambium Oncology.